IRIS - Res&Arch Institutional Research Information System - Research & Archive

FANELLI, Carmine Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.150
EU - Europa 2.851
AS - Asia 739
OC - Oceania 10
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 1
Totale 6.761
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.140
IE - Irlanda 592
UA - Ucraina 575
SE - Svezia 503
IT - Italia 434
SG - Singapore 236
HK - Hong Kong 204
FI - Finlandia 162
CN - Cina 151
DE - Germania 148
RU - Federazione Russa 142
FR - Francia 97
VN - Vietnam 85
GB - Regno Unito 71
TR - Turchia 30
AT - Austria 25
CH - Svizzera 19
CZ - Repubblica Ceca 16
NL - Olanda 16
GR - Grecia 11
BE - Belgio 10
AU - Australia 9
PL - Polonia 9
KR - Corea 8
UZ - Uzbekistan 8
ES - Italia 7
RO - Romania 6
CA - Canada 5
LB - Libano 5
MX - Messico 5
JP - Giappone 4
AR - Argentina 3
BR - Brasile 3
EE - Estonia 3
EU - Europa 3
ID - Indonesia 3
IN - India 3
IM - Isola di Man 2
BH - Bahrain 1
CI - Costa d'Avorio 1
CL - Cile 1
HU - Ungheria 1
LI - Liechtenstein 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
PH - Filippine 1
Totale 6.761
Salva come PNG Salva come JPEG
Città #
Chandler 684
Dublin 592
San Mateo 346
Jacksonville 269
Hong Kong 203
Altamura 192
Medford 171
Princeton 169
Singapore 150
Wilmington 144
Lawrence 129
Perugia 101
Ann Arbor 88
Des Moines 86
Dong Ket 85
Andover 78
Boardman 74
Beijing 54
Saint Petersburg 53
Falls Church 35
Helsinki 35
New York 33
Ashburn 29
Izmir 28
Woodbridge 27
Norwalk 25
Los Angeles 22
Rome 21
Fremont 16
Amelia 15
San Paolo di Civitate 15
Redmond 14
Moscow 13
Brno 11
Auburn Hills 10
Brussels 10
Vienna 10
Cáceres 7
Redwood City 7
Shanghai 7
Den Haag 6
Frankfurt Am Main 6
Houston 6
Renton 6
San Diego 6
Seoul 6
Bucu 5
Rotterdam 5
Terni 5
Bologna 4
Chicago 4
Collazzone 4
Columbia 4
Lappeenranta 4
Lausanne 4
Melbourne 4
Olomouc 4
Salerno 4
Sinalunga 4
Amsterdam 3
Bolton 3
Spoleto 3
Surrey 3
Tallinn 3
Tappahannock 3
Arezzo 2
Athens 2
Catania 2
Douglas 2
Fairfield 2
Frankfurt am Main 2
Grandate 2
Hamburg 2
Hyderabad 2
Istanbul 2
Jose C. Paz 2
Leipzig 2
León 2
Magelang 2
Manassas 2
Nürnberg 2
Osoppo 2
Perth 2
Philadelphia 2
Plaistow 2
Plymouth 2
Segrate 2
Selargius 2
Spring 2
Swansea 2
Sydney 2
Thessaloniki 2
Turin 2
Abidjan 1
Ariano nel Polesine 1
Atlanta 1
Belo Horizonte 1
Boston 1
Brisbane 1
Budapest 1
Totale 4.230
Salva come PNG Salva come JPEG
Nome #
Different brain responses to hypoglycemia induced by equipotent doses of long-acting insulin analog detemir and human regular insulin in humans 113
Adrenaline vs glucagon in the primacy of glucose counterregulation 97
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules. 93
Administration of neutral protamine Hagerdon insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. 92
Blood-to-brain glucose transport and cerebral glucose metabolism are not reduced in poorly controlled type 1 diabetes 80
An intensive lifestyle intervention in children with attention-deficit/hyperactivity disorder 78
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 74
IMPACT OF NOCTURNAL HYPOGLYCEMIA ON HYPOGLYCEMIC COGNITIVE DYSFUNCTION IN TYPE 1 DIABETES 73
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. 71
Nocturnal blood glucose control in type I diabetes mellitus. 70
Administration of Neutral Protamine Hagedorn insulin at bedtime versus dinner in Type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control: a randomized, controlled trial. 70
Early improvement of glucose tolerance after ileal transposition in a nonobese Type 2 diabetes rat model. 69
Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia 64
Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study. 64
Effects of an Intensive Lifestyle Intervention to Treat Overweight/Obese Children and Adolescents 64
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs 63
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 63
Uso dell’analogo ad azione rapida lispro con l’analogo ad azione ritardo glargine nel trattamento intensivo del T1DM 62
Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. 62
Adrenergic mechanisms do not contribute to glucose counterregulation during acute insulin-induced hypoglycaemia in normal man. 62
18. Insulin required for prandial ghrelin suppression in humans 61
The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity 61
Intensive lifestyle intervention is particularly advantageous in poorly controlled type 2 diabetes 61
Cognitive function in hypoglycaemia 58
Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. 58
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules 57
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in Type 2 diabetes. 57
Premeal Insulin Treatment During Basal-Bolus Regimen in Young Children With Type 1 Diabetes 57
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia 56
Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. 56
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans. 56
Physical activity habits and well-being among 6-year-old children: The “improving umbrian kids’ healthy lifestyle”, an uncontrolled pilot study project 56
Counterregulatory responses in CSII 55
Ipoglicemia: cause e prevenzione 55
Hypoglycemia 55
A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules. 54
Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. 54
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting analogue at mealtime. A three month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. 53
Counterregulatory hormone and symptom responses to insulin-induced hypoglycaemia in the postprandial state in humans 52
A novel surrogate index for hepatic insulin resistance. 52
Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans 51
Impact of recent antecedent hypoglycemia on hypoglycemic cognitive dysfunction in nondiabetic humans. 51
Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis 51
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. 51
Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. 50
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes mellitus. 50
Shift of glycaemic thresholds for cognitive function in hypoglycaemia unawareness in humans. 50
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro 50
null 49
Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus 49
Physical activity level and mediterranean diet adherence evaluation in older people - observational, uncontrolled, pilot study 49
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 48
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 48
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 48
Intensive replacement of basal insulin in patients with Type 1 diabetes mellitus given rapid-acting insulin analogue at meal-time: a three-month comparison between administration of NPH four times daily and glargine insulin at dinner or bedtime. 47
Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. 47
Glucagon: the effects of its excess and deficiency on insulin action 46
Responses to hypoglycemia in diabetic autonomic neuropathy. 46
Insulin is required for prandial ghrelin suppression in humans 46
Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. 45
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic people. 45
Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus 44
Sertoli cell-induced reversal of adult rat pancreatic islet beta-cells into fetal-like status: potential implications for islet transplantation in type I diabetes mellitus 43
Quando “i conti non tornano” (Caso clinico) G It Diabetol Metab 26:172-175 42
Insulin therapy and hypoglycemia: the size of the problem 42
Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. 42
Hyperglycemia, Both Chronic and in Short-Term Peaks, Results in Rapid Increase of Expression of Monocyte Inducible Cyclooxygenase (COX-2) in Subjects with T2DM 42
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study 42
Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans. 41
Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. 41
L’ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla 41
Effects of a supervised nordic walking program on obese adults with and without type 2 diabetes: The C.U.R.I.A.Mo. Centre experience 41
Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning 40
La terapia insulinica nel diabete mellito tipo 2. 40
Is physical activity a necessary element during Italian coronavirus disease emergency? Yes or no debate 40
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 39
Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. 39
Mechanisms of arterial hypotension after therapeutic dose of subcutaneous insulin in diabetic autonomic neuropathy. 39
Low levels of unmodified insulin glargine in plasma of people with type 2 diabetes requiring high doses of basal insulin 39
Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes 39
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus 39
Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes 39
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. 38
Recovery and prevention of hypoglycaemia unawareness in Type 1 diabetes mellitus 38
Circulating ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement 38
PHARMACOKINETIC AND PHARMACODYNAMIC HEAD-TO-HEAD COMPARISON OF CLINICAL, EQUIVALENT DOSES OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC 100 U/ML IN TYPE 1 DIABETES 38
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. 37
Late post-prandial hypoglycaemia as the sole presenting feature of secreting pancreatic beta-cell adenoma in a subtotally gastrectomized patient. 37
Circulatin ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement 37
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. 37
Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. 37
Ricoveri per ipoglicemia grave in soggetti con diabete mellito di tipo 2: impatto clinico e costi sanitari 37
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 36
Contribution of cortisol to glucose counterregulation in humans 36
Diabete ­e ­cancro. 36
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study 36
Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: The Importance of appropriate resuspension before subcutaneous injection 36
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes mellitus. 35
Plasma leptin and insulin relationships in obese and nonobese humans. 35
Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension. 34
Totale 5.137
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.189
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.189
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020527 34 12 78 6 67 34 87 10 98 46 15 40
2020/20211.297 5 97 69 85 383 115 78 15 172 58 103 117
2021/20221.282 29 233 30 83 34 20 20 407 16 32 137 241
2022/20232.310 184 465 31 191 170 287 5 95 788 3 67 24
2023/2024999 54 105 43 33 8 8 205 14 81 39 187 222
2024/202532 32 0 0 0 0 0 0 0 0 0 0 0
Totale 7.064